Document is current
Any future updates will be listed below
-
Authors
Everard, Isabel M.
de Veer, Michael J.
Kwan, Edmond M.
Lister, Natalie L.
Keerthikumar, Shivakumar
Ryan, Andrew
Sivaratnam, Dinesh
Haskali, Mohammad B.
Risbridger, Gail P.
Porter, Laura H. https://orcid.org/0000-0002-2650-3365
Taylor, Renea A. https://orcid.org/0000-0003-2609-2380
-
Funding
Funding for this research was provided by:
Cancer Council Victoria (Venture Grant)
Cancer Council Victoria (TP834128)
Faculty of Medicine, Nursing and Health Sciences, Monash University (FLPF23-1952570271)
Faculty of Medicine, Nursing and Health Sciences, Monash University (Bridging Fellowship)
National Health and Medical Research Council (2026555)
National Health and Medical Research Council (2011391)
National Health and Medical Research Council (2011391)
Prostate Cancer Foundation of Australia (PIRAYI-0322)
Endocrine Society of Australia (Postdoctoral Award)
Tour de Cure (RSP-515-2024)
Victorian Cancer Agency (MCRF15023)
- License Information
-
More Information
Article History
Received: 26 November 2025
Accepted: 31 January 2026
First Online: 13 February 2026
Declarations
:
: For the establishment of patient-derived xenografts, informed, written consent was obtained from patients prior to tissue collection according to human ethics approval from the Cabrini Institute (RES-20-0000-107 C; 03-14-04-08), Monash University (1636; 7996) and Peter MacCallum Cancer Centre (11/102). All animal care and procedures for the establishment, maintenance and treatment of PDXs were performed in accordance with Monash University animal ethics approvals (28911; 31041; 37507; 41088).
: Not applicable.
: R Taylor and G Risbridger have existing research collaborations with Pfizer, Astellas, Zenith Epigenetics, AstraZeneca. M. de Veer has existing contract research projects with Telix Pharmaceuticals that are unrelated to this study.
